Pfizer's Xeljanz Gains FDA Panel Nod In Psoriatic Arthritis, But Labeling Questions Remain
US advisory committee recommends approval of new indication for the JAK inhibitor but does not want any radiographic progression data in labeling amid questions about effect.
